- The Middle East and Africa Hepatitis Delta Virus (HDV) Infection market is experiencing significant growth due to increasing awareness, improved diagnostic capabilities, and enhanced access to healthcare services across developing countries in the region
- The growing burden of liver-related diseases, rising healthcare expenditures, and government-led hepatitis elimination programs are the primary factors driving market expansion in the Middle East and Africa
- Saudi Arabia dominated the Middle East and Africa hepatitis delta virus (HDV) infection market with the largest revenue share of 36.84% in 2024, driven by its robust healthcare infrastructure, high prevalence of hepatitis B (a prerequisite for HDV), and expanding use of advanced diagnostic and therapeutic modalities
- Egypt is expected to witness the fastest-growing CAGR of 6.9% in the Middle East and Africa hepatitis delta virus (HDV) infection market during the forecast period, fueled by rising healthcare awareness, strong public health campaigns targeting liver diseases, and increasing government and NGO collaboration for hepatitis screening and treatment access
- The Parenteral route of administration segment dominated the Middle East and Africa hepatitis delta virus (HDV) infection market with a share of 66.5% in 2024, supported by the widespread use of injectable pegylated interferon as the standard treatment, ensuring effective viral suppression and alignment with established clinical protocols
